Ono enters into drug discovery collaboration agreement with Twist Bioscience for novel antibodies for autoimmune diseases

Ono Pharmaceutical has entered into a drug discovery collaboration agreement with Twist Bioscience to discover and develop innovative antibodies for autoimmune diseases.

Under the terms of the agreement, Twist will utilize the Twist Biopharma Solutions Library of Libraries to conduct research activities to discover novel antibodies against therapeutic target(s) identified by Ono.

Twist’s Library of Libraries is an expansive collection of synthesized antibody libraries based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of drug targets.

Ono will retain exclusive rights to globally develop, manufacture and commercialize therapeutic antibody drugs generated through the collaboration. Ono will pay to Twist research fees, and success-based clinical and regulatory milestones, as well as tiered royalties based on global net sales.

“We are actively working to create biologics like antibodies in order to address unmet medical needs for a wide range of diseases including autoimmune diseases. We are very pleased to collaborate with Twist this time in the area of autoimmune diseases and are confident that their expertise in antibody discovery and their impressive collection of diverse and highly specific antibody libraries will bring us potential functional antibodies,” said Dr. Toichi Takino, Senior Executive Officer / Executive Director, Discovery and Research of Ono.

“We believe that this new collaboration will enhance our biologics drug discovery efforts and bring innovative drugs for patients with autoimmune diseases as soon as possible.”

“Ono has a strong and proven track record in developing antibody candidates in areas of need, including the anti-PD-1 antibody Opdivo, which has had a tremendous impact for patients and researchers,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

“This collaboration, bringing together our antibody discovery expertise with Ono’s experience in drug development, has the potential to lead to future breakthrough treatment options for patients with autoimmune diseases.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news